BAVARIAN NORDIC/S to Post Q3 2019 Earnings of ($0.22) Per Share, Jefferies Financial Group Forecasts (OTCMKTS:BVNRY)

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) – Jefferies Financial Group issued their Q3 2019 earnings per share estimates for shares of BAVARIAN NORDIC/S in a research note issued to investors on Wednesday, October 23rd. Jefferies Financial Group analyst P. Welford expects that the company will post earnings of ($0.22) per share for the quarter. Jefferies Financial Group also issued estimates for BAVARIAN NORDIC/S’s Q4 2019 earnings at $0.01 EPS, FY2019 earnings at ($0.55) EPS, FY2020 earnings at ($0.10) EPS, FY2021 earnings at $0.09 EPS, FY2022 earnings at $0.46 EPS and FY2023 earnings at $0.19 EPS.

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) last posted its earnings results on Thursday, August 15th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). BAVARIAN NORDIC/S had a negative return on equity of 12.47% and a negative net margin of 42.42%. The firm had revenue of $15.26 million for the quarter, compared to analysts’ expectations of $19.80 million.

Separately, Zacks Investment Research raised BAVARIAN NORDIC/S from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a research report on Friday.

Shares of BVNRY opened at $8.83 on Monday. The company has a quick ratio of 7.52, a current ratio of 7.93 and a debt-to-equity ratio of 0.23. The business’s 50 day moving average price is $8.86 and its 200-day moving average price is $8.11. BAVARIAN NORDIC/S has a 52 week low of $5.92 and a 52 week high of $10.93. The stock has a market cap of $855.99 million, a P/E ratio of -14.97 and a beta of 0.61.


Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus.

Featured Article: What Factors Can Affect Return on Equity?

Receive News & Ratings for BAVARIAN NORDIC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC/S and related companies with's FREE daily email newsletter.